维奈克拉联合吉瑞替尼在FLT3突变型BCL11B激活的谱系不明白血病临床前模型中有效
BCL11B激活(BCL11B-a)定义了一类兼具T淋巴与髓系特征的谱系不明白血病,常合并FLT3激活突变,缺乏最佳治疗方案。本研究在BCL11B-a白血病临床前模型中评估BCL-2抑制剂维奈克拉与FLT3抑制剂吉瑞替尼的疗效,发现尽管单药反应不一,维奈克拉联合吉瑞替尼(VenGilt)在所有评估模型中均高度有效。BH3谱分析提示维奈克拉单药耐药与治疗前肿瘤对额外BCL-2家族蛋白的依赖有关,纵向单细胞RNA测序发现线粒体通路和促淋系基因表达特征可能是VenGilt治疗下罕见细胞存活的驱动因素。
要点
- 维奈克拉联合吉瑞替尼在全部评估的BCL11B-a白血病临床前模型中高度有效。
- 维奈克拉单药耐药与治疗前肿瘤对额外BCL-2家族蛋白的依赖有关。
- 线粒体通路和促淋系基因表达特征可能与VenGilt治疗下罕见细胞存活相关。
核心结论
- 维奈克拉联合吉瑞替尼在BCL11B-a谱系不明白血病临床前模型中高度有效,支持开展临床评估。
研究设计与样本
- 在BCL11B-a白血病临床前模型中评估维奈克拉与吉瑞替尼单药及联合(VenGilt)的疗效。
主要发现
- 尽管单药治疗反应存在差异,维奈克拉联合吉瑞替尼在所有评估模型中均高度有效。
- BH3谱分析提示维奈克拉单药耐药源于治疗前肿瘤对额外BCL-2家族蛋白的依赖。
- 纵向单细胞RNA测序分析识别出线粒体通路和促淋系基因表达特征,可能是VenGilt治疗下罕见细胞存活的驱动因素。
临床怎么用
- 作者认为这些数据支持在BCL11B-a谱系不明白血病中开展维奈克拉联合吉瑞替尼的临床评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aberrant activation of BCL11B (BCL11B-a) defines a subtype of lineage-ambiguous leukemias with T-lymphoid and myeloid features, co-occurring activating FLT3 mutations, and a stem/progenitor immunophenotype and gene expression profile. Similar to other lineage-ambiguous leukemias, optimal treatment is unclear, and there are limited targeted therapeutic options. Here, we investigated the efficacy of B-cell lymphoma 2 (BCL-2) and FMS-like tyrosine kinase 3 (FLT3) inhibition with venetoclax and gilteritinib, respectively, in preclinical models of BCL11B-a leukemia. Despite variation in response to single-agent therapies, the combination of venetoclax plus gilteritinib (VenGilt) was highly effective in all models evaluated. BH3 profiling suggested that resistance to venetoclax monotherapy was due to the tumor-intrinsic dependence on additional BCL-2 family proteins before drug treatment. Longitudinal single-cell RNA sequencing analysis identified mitochondrial pathways and a pro-lymphoid gene expression signature as potential drivers of rare cell survival on VenGilt therapy. These data support clinical evaluation of venetoclax in combination with gilteritinib in BCL11B-a lineage-ambiguous leukemias.
引用
- Montefiori LE, Iacobucci I, Gao Q, et al. Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia. Blood. 2025. PMID: 40811853. doi:10.1182/blood.2025028985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。